ATOS — ATOSSA THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1488039 ·
Last close
$1.90
Market Cap
$18.96M
52W High
$14.85
52W Low
$1.70
ADV30
81,256
Next earnings
—
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -5,899,000 -5,638,000 26,448,000 20,574,000 4,709,000
Jun 2026 0 — -8,694,000 -8,491,000 32,281,000 26,094,000 5,451,000
Mar 2026 0 — -9,870,000 -9,589,000 37,943,000 31,718,000 7,457,000
Dec 2025 0 — -11,436,000 -10,937,000 47,608,000 41,299,000 8,255,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-35,284,000
Investing CF
$-7,000
Financing CF
$0
CapEx
$-23,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.63
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-270,280,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-35,899,000
Pretax Income TTM
$-34,655,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -37,141,000 -34,770,000 47,608,000 8,255,000 39,353,000 -29,762,000
Dec 2024 0 -27,621,000 -25,504,000 76,444,000 4,967,000 71,477,000 -21,030,000
Dec 2023 0 -31,377,000 -30,094,000 96,252,000 5,236,000 91,016,000 -20,941,000
Dec 2022 0 -27,691,000 -26,960,000 123,532,000 5,568,000 117,964,000 -20,760,000

TTM Snapshot

Revenues TTM
$1,548,000
NetIncome TTM
$-37,709,000
OpCashFlow TTM
—
Assets (Latest)
$32,281,000
Forward EPS
$-3.30

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.00 · spot: $1.81 · call volume: 27 · put volume: 7
Expected Move to 2027-01-15: ±$0.68 (37.29%) — implied range $1.14 – $2.49 · ATM straddle on $2.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EDSA Edesa Biotech, Inc. $18.90M $1.96 —
CELU Celularity Inc $18.53M $0.57 —
IGC IGC Pharma, Inc. $19.43M $0.19 —
COCP Cocrystal Pharma, Inc. $19.46M $1.01 —
PVCT PROVECTUS BIOPHARMACEUTICALS, INC. $17.90M $0.04 —

News headlines (Yahoo Finance, 1h cache)

Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-10 13:15 · Yahoo
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
2026-10-19 12:00 · Yahoo
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
2026-10-09 12:00 · Yahoo
Atossa plans shareholder stake in potential PRV proceeds
2026-09-30 17:18 · Yahoo
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
2026-09-29 12:00 · Yahoo
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
2026-09-24 12:00 · Yahoo
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
2026-08-07 12:45 · Yahoo
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
2026-07-28 12:30 · Yahoo
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
2026-07-21 12:30 · Yahoo
ATOS: Raises up to $16.5 Million in Registered Direct Offering
2026-07-01 13:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.